Citation Impact
Citing Papers
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
2003 StandoutScience
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
2003 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Evolution of the Cancer Stem Cell Model
2014 Standout
Ingested Type I Interferon: A Potential Treatment for Autoimmunity
2002
Cancer treatment and survivorship statistics, 2022
2022 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
2012 Standout
Oncogenic kinase signalling
2001 StandoutNature
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
2002 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
How many drug targets are there?
2006 Standout
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
2001 Standout
Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology
2000
Cancer Statistics, 2006
2006 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
2001
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
Acute lymphoblastic leukaemia
2013
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
1996 Standout
Molecular evolution of acute myeloid leukaemia in relapse: unstable N‐ras and FLT3 genes compared with p53 gene
1999
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
2006 Standout
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
2005 Standout
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222
2004
Cancer genes and the pathways they control
2004 Standout
Biology of Natural Killer Cells
1989 Standout
STATs in oncogenesis
2000 Standout
Protein kinases — the major drug targets of the twenty-first century?
2002 Standout
Chronic Myelogenous Leukemia
2002
OPTIONS FOR THERAPY IN CHRONIC MYELOID LEUKAEMIA
1995
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia
2001
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor
2000 StandoutNobel
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission.
1989 StandoutNobel
Imatinib Mesylate — A New Oral Targeted Therapy
2002
ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome
2007 Standout
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
2003 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
1997 Standout
A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16
2006
Remission induction in children with acute non‐lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: A report from the childrens cancer study group
1989
Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays
2000 Standout
Interferon-γ: an overview of signals, mechanisms and functions
2003 Standout
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
2012 StandoutNobel
Childhood lymphoblastic leukemia with natural killer activity: establishment of the leukemia cell lines retaining the activity
1982
Childhood acute lymphoblastic leukemia with natural killer activity. Clinical and cellular features of three cases
1984
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
2001
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Functional Role of Type I and Type II Interferons in Antiviral Defense
1994 StandoutScience
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
2004 StandoutNobel
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
2004 StandoutScience
Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine
1999
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
1999
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
1999
Cancer treatment and survivorship statistics, 2016
2016 Standout
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
2001 Standout
Cancer treatment and survivorship statistics, 2019
2019 Standout
Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays
1998 Standout
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
2005
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
2000 StandoutScience
Acute nonlymphocytic leukemia: heterogeneity of stem cell origin
1981
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
Cytokine therapeutics: lessons from interferonalpha.
1994
GENETICS OF MYELOID LEUKEMIAS
2002
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
2001
JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis
2010 StandoutNobel
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
2001
Serum lactic dehydrogenase level has prognostic value in childhood acute lymphoblastic leukemia
1985
Cancer treatment and survivorship statistics, 2014
2014 Standout
Chronic Myelogenous Leukemia: Biology and Therapy
1999
Works of SL George being referenced
An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B
1998
Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia
1982
Initial prognostic factors and lymphoblast-erythrocyte rosette formation in 109 children with acute lymphoblastic leukemia
1977
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia
1994
Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583 [see comments]
1993
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia
1994
Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia
1987